Repros Therapeutics (RPRX) reported a Q1 loss that was slightly higher than analysts had expected due to increased headcount.
The developer of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders said its Q1 loss was $8.5 million, or $0.37 per share, compared to $7.4 million, or $0.41, the year earlier. Analysts polled by Capital IQ had expected a loss of $0.35 per share.
Revenues were $2,000 up from $1,000 a year ago on increased interest income on higher cash balances. Research and development expenses rose 16% on legal expenses, payroll and benefits expenses as well as clinical development expenses.
RPRX was up 0.8% in recent trade, near the lower end of the 52-week range between $13.93 and $29.79.
Latest posts by Kevin Calderon (see all)
- Expedition 50 Of The ISS Just Broke Another Record - Apr 26, 2017
- Researchers Found Live Giant Shipworm That Feeds On Sulfur? - Apr 19, 2017
- Hawaiian Telescope Led To The Discovery Of A Primordial Galaxy - Apr 14, 2017